GAM
PETX

Gotham Asset Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Gotham Asset Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,017
Closed -$112K – 1109
2016
Q3 		$112K Buy
+12,017
New +$99.8K ﹤0.01% 898

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gotham Asset Management's PETX Position: Q4 2016 in Review

Gotham Asset Management sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2016, closing a stake of 12,017 shares — an estimated $112K sold.

Gotham Asset Management first reported a position in PETX in Q3 2016 and held it in 1 quarter. The position peaked at $112K in Q3 2016. 107 funds tracked by Wall St. Rank hold PETX as of Q4 2016.

  • Gotham Asset Management reported no remaining Aratana Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Gotham Asset Management sold 12,017 Aratana Therapeutics, Inc. shares in Q4 2016, an estimated $112K.
  • Gotham Asset Management first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Gotham Asset Management's Aratana Therapeutics, Inc. position peaked at $112K in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2016.

Based on Gotham Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.